Mubadala Leads $4.2bn Buyout Of UK Biotech CMC As Life-Sciences M&A Reawakens

Abu Dhabi's Mubadala Investment Company is leading a $4.2 billion all-cash bid to take UK-listed biotech CMC Therapeutics private, in a deal that gives the Cambridge-based contract-research and clinical-development specialist a 38% premium to its undisturbed share price and signals that life-sciences M&A is reawakening after a sustained dry spell.

The bidding consortium includes Mubadala's life-sciences vertical, Singapore's GIC, and a co-investment vehicle anchored by Japan's Mitsubishi Tanabe Pharma. The structure gives Mubadala roughly 47% of the equity at completion, with strategic intent that the company has openly framed as positioning around the convergence of high-throughput biotech services and the AI-enabled drug-discovery pipeline that several major pharmaceutical clients are now actively building.

CMC's board has unanimously recommended the offer, subject to a 21-day go-shop window that the deal documentation makes clear is genuine rather than perfunctory. The company's largest institutional shareholder, Baillie Gifford, has given an irrevocable undertaking to vote in favour — usually a strong signal that competing bids are unlikely to emerge unless they meaningfully exceed the agreed price.

Strategically, the deal sits at an interesting interface. CMC has built a meaningful franchise in cell-and-gene-therapy manufacturing-process development — an area where capacity remains scarce and pricing power has been demonstrably durable. Mubadala's wider life-sciences holdings include investments in the Massachusetts and Genomics Englands ecosystems, and the company is openly building toward an integrated services-plus-discovery position that the public-markets format has not adequately rewarded.

The deal is also a signal moment for the UK listing environment. CMC was held up through 2024 and 2025 as evidence of the under-valuation problem affecting London-listed mid-cap science companies; the takeout at this premium will reinforce both the bull case for those still listed and the brain-drain narrative. For the M&A read-across, however, the more important point is the buyer profile: sovereign-anchored capital with strategic intent now commands the cleanest path through public-markets gates.